Over £435,000 awarded to new research exploring ways to manage Parkinson’s symptoms Date 2 April 2025
Phase 3 trial of ambroxol is underway Date 1 April 2025 The first participant has received either ambroxol or the placebo in the ASPro-PD trial. This marks the start of 330 people with Parkinson’s taking a component of an already approved drug over 2 years to see if it is beneficial.
New centre to accelerate Parkinson’s research Date 7 March 2025 Parkinson’s UK and the UK Dementia Research Institute (UK DRI) join forces to establish a pioneering research centre.
Global cases of Parkinson’s predicted to rise to 25 million by 2050 Date 5 March 2025 A study predicting health trends worldwide suggests that incidence of Parkinson’s is rising due to an ageing population.
Future leaders in research recognised with Parkinson’s UK funding award Date 11 February 2025 Nearly £600,000 has been awarded to 2 outstanding scientists to develop their Parkinson’s research careers.
Results from the phase 3 trial of exenatide published Date 4 February 2025 The full results show that exenatide had no benefits over the placebo and didn’t slow the progression of Parkinson’s.
Adaptive deep brain stimulation in the news Date 29 January 2025 Adaptive deep brain stimulation in the news
Blood pressure drug shows promise for reducing tremor in Parkinson’s Date 9 January 2025 A small study of a drug called propranolol looked effective in easing tremor both at rest and in stressful situations for people with Parkinson’s.
Our trial of ondansetron as a treatment for hallucinations in Parkinson's is restarting Date 22 November 2024 The TOP HAT trial was halted in April. We’re delighted to announce that it is restarting.
Parkinson’s UK awards £1m to new research projects Date 5 November 2024 Parkinson’s UK has granted funding to projects aiming to advance our understanding of the causes and symptoms of Parkinson’s, as well as exploring new treatments.
Results from the phase 3 trial of exenatide shared with participants Date 15 October 2024 The results indicate that people in the study who received exenatide did not benefit compared to those who received placebo - suggesting that the drug does not slow down the progression of Parkinson’s.
